Author:
Elwood Fiona,Witter David J.,Piesvaux Jennifer,Kraybill Brian,Bays Nathan,Alpert Carla,Goldenblatt Peter,Qu Yujie,Ivanovska Irena,Lee Hyun-Hee,Chiu Chi-Sung,Tang Hao,Scott Mark E.,Deshmukh Sujal V.,Zielstorff Mark,Byford Alan,Chakravarthy Kalyan,Dorosh Lauren,Rivkin Alexey,Klappenbach Joel,Pan Bo-Sheng,Kariv Ilona,Dinsmore Christopher,Slipetz Deborah,Dandliker Peter J.
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmacology,Molecular Medicine
Reference30 articles.
1. Ahearn SP, Christopher M, Jung J, Pu Q, Rivkin A, Scott ME, Witter DJ, Woo HC, Cash B, Dinsmore C, et al (2013) inventors, Merck Sharp & Dohme Corporation, assignee. Pyrrolopyrimidines as janus kinase inhibitors. Patent WO 2013085802 A1. 2013 Jun 13.
2. Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3;Brown;Blood,1999
3. Brubaker J, Dinsmore CJ, Hoffman DM, Jung J, Liu D, Peterson S, Siu T, Torres LE, Zhang H, Wei Z, et al. (2013) inventors, Merck Sharp & Dohme Corporation, assignee. Cyanocycloalkyl pyrazole carboxamides as janus kinase inhibitors. Patent WO 2013040863 A1. 2013 Mar 28.
4. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
5. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献